Preceeding the rejection: In search for a comprehensive post-transplant immune monitoring platform

Transplant Immunology

Volumn 18, Issue 1, 2007, Pages 7-12

  Israeli, Moshe ^a,b   Yussim, Alex ^a   Mor, Eitan ^a   Sredni, Benjamin ^b   Klein, Tirza ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Immune monitoring; Monitoring; Organ transplantation; Post transplant

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD30 ANTIGEN; HLA ANTIBODY; PHYTOHEMAGGLUTININ;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; GRAFT FAILURE; GRAFT INFECTION; GRAFT SURVIVAL; HUMAN; IMMUNE FUNCTION TEST; IMMUNOLOGICAL MONITORING; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTIGENS, CD30; CALCINEURIN; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KIDNEY TRANSPLANTATION; MONITORING, IMMUNOLOGIC;

EID: 34250328218     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2007.03.005     Document Type: Article

References (12)

1. Hricik D.E., and Heeger P.S. Minimization of immunosuppression in kidney transplantation. The need for immune monitoring. Transplantation 72 (2001) S32-S35
2. Martinez O.M., Villanueva J., Abtahi S., Beatty P.R., Esquivel C.O., and Krams S.M. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 65 (1998) 1240-1247
3. Kowalski R., Post D., Schneider M.C., Britz J., Thomas J., Deierhoi M., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17 (2003) 77-88
4. Kowalski R.J., Post D.R., Mannon R.B., Sebastian A., Wright H.I., Sigle G., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
5. Cardarelli F., Pascual M., Tolkoff-Rubin N., Delmonico F.L., Wong W., Schoenfeld D.A., et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 18 (2005) 532-540
6. Phelan D. New Methods for the Detection of Antibodies (Sensitization) to Human Leukocyte Antigens. ASHI Quarterly Fourth Quarter (2001) 147pp.
7. Terasaki P.I., and Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 17 (2005) 541-545
8. Hourmant M., Cesbron-Gautier A., Terasaki P.I., Mizutani K., Moreau A., Meurette A., et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 16 (2005) 2804-2812
9. Slavcev A., Lacha J., Honsova E., Sajdlova H., Lodererova A., Vitko S., et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 14 (2005) 117-121
10. Susal C., Pelzl S., Dohler B., and Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13 (2002) 1650-1656
11. Pelzl S., Opelz G., Daniel V., Wiesel M., and Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75 (2003) 421-423
12. Romagnani S., Del Prete G., Maggi E., Chilosi M., Caligaris-Cappio F., and Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 57 (1995) 726-730